Dis-Chem's management said the consumer affordability pressures proved more persistent than anticipated in its 2026 financial year.
Image: Karen Sandison / Independent Newspapers
Dis-Chem remains well positioned to benefit from the growing demand for accessible healthcare and wellness solutions in South Africa, even though the broader operating environment is expected to remain challenging, chairman Larry Nestadt said.
The group’s shares trade at R32.70 on Friday afternoon on the JSE, but the price has fallen by more than 16% since its annual results were published in May. CEO Luis Morais said in the annual report that the group’s management and board are “acutely aware that shareholders who invested in Dis-Chem for its earnings track record have seen a year of disappointing reported results.”
The maturing of the group’s Better Rewards programme and further customer engagement gains, the launch of the new Dis-Chem app, and the expansion of omnichannel capabilities, along with progressive returns from the X, bigly labs ecosystem investment, as well as data, analytics, and the operationalization of AI platforms, were growing the group, he said in the integrated report.
Wholesale market share opportunities would continue to be gained through CJ Distribution, TLC franchise stores, and independent pharmacy relationships. Operational and supply chain optimisation are continuing, and integrated healthcare services, including Dis-Chem Health and Dis-Chem Life, are being expanded.
“The board remains focused on supporting sustainable, long-term growth while maintaining prudent financial management, disciplined capital allocation, and strong governance standards. The group’s integrated healthcare ecosystem, trusted brand, national footprint, and experienced leadership team provide a solid foundation for future growth," said Nestadt.
He said the board acknowledged that the decline in EPS (earnings per share) and HEPS (headline earnings per share) in the 2026 financial year – driven primarily by the front-loaded ecosystem investment – directly affected short-term incentive outcomes and the declared dividend per share.
“The final dividend of 15.92 cents per share reflects this, and the board recognises that balancing appropriate reward with the economic realities facing shareholders requires ongoing thoughtfulness,” he said.
“The R330 million invested in X, bigly labs, the non-recurring costs of transitioning from Benefit Points to Better Rewards, and the ongoing costs of scaling our healthcare ecosystem all reduced reported earnings this year. We accepted this willingly,” said Morais.
“My commitment is to transparency: the investment rationale is sound, and the early proof shows The launch of Better Rewards achieved 9,6% revenue growth among participating brands and 18,7% volume growth in the first 17 weeks.
He said they achieved market share gains across all core retail categories, including dispensary, healthcare and medical, personal care and beauty, and baby care. Thirty-three new retail pharmacy stores were opened, and the total pharmacy footprint reached 316 stores.
The Health Hub store-of-the-future format was advanced, integrating healthcare services, digital engagement, and retail. Dis-Chem Health and Dis-Chem Life grew, contributing to ecosystem revenue diversification.
External wholesale revenue expanded by 11,3%, with the TLC franchise network growing to 193 clinics. X, bigly labs was established, with significant progress in digital platform stability, cybersecurity, and data infrastructure. Inventory days reduced to 86 from 91, and cash generated from operations doubled to R1,8 billion.
Reflecting on the past year, Morais said consumer affordability pressures proved more persistent than anticipated. The healthcare and digital landscape continued to evolve faster than legacy systems could keep pace. The volume of simultaneous strategic initiatives – Better Rewards, X, bigly labs, Health Hub, and healthcare ecosystem expansion – created execution complexity that was being actively managed.
Dis-Chem serves multiple, interconnected markets through an integrated operating model that combines retail, wholesale, digital, and healthcare services. The group’s primary market is the South African consumer seeking trusted access to prescription medicines, over-the-counter products, healthcare and wellness solutions, personal care and beauty products, and baby care essentials.
Dis-Chem’s wholesale division is a critical component of its market reach, serving more than 1,600 independently owned pharmacies, representing a significant share of the independent pharmacy market in South Africa. This positions the group as a critical enabler within the broader healthcare ecosystem, extending its reach beyond its owned retail footprint and supporting the sustainability of independent pharmacy operators.
Visit:www.businessreport.co.za